Quantitative assessment of HBsAg in the process of treatment of chronic hepatitis В with pegilated interferon alpha-2a (Pegasis): a new tool for the prediction of effective treatment


Cite item

Full Text

Abstract

The article is dedicated to modern concepts of infection caused by the hepatitis B virus (HBV), and approaches to antiviral therapy of chronic hepatitis B (CHB). One of the fundamentally new approaches in the evolution of antiviral treatment of CHB was the use of pegylated interferon alpha. Among the high number of patients the most explored and tested drug is pegylated interferon alfa-2a (40 kDa; Pegasys). It was shown that the treatment of CHB by this drug should be considered as first-line therapy in young patients with no signs of disease decompensation. To date, treatment of HBV by Pegasys is characterized by high frequency of HBsAg elimination and appearance of anti-HBs that is associated not only with direct antiviral action of the drug, but also with ability to influence the immune response. Quantitative measurement of HBsAg in the process of CHB treatment is a new tool for predicting effectiveness of antiviral therapy with pegylated interferon alfa-2a.

References

  1. Koff R. Chronic viral hepatitis. Humana Press, New Jersey. 2006;340.
  2. Feldmann M, Friedmann L, Sleisinger M. Gastrointestinal and Liver Disease. 9th Edition. Saunders 2009;1278-334.
  3. Cheung RC. Epidemiology of hepatitis B virus infection in Asian and European population. J Hepatology 2000;45:740-47.
  4. Tradati F, Colombo M. Prospective multicenter study of hepatocellular carcinoma in hemophiliacs. Blood 1998;91:1173-77.
  5. Шахгильдян И. В. Эпидемиологические аспекты хронических вирусных гепатитов/ Материалы XIV Российской конференции «Гепатология сегодня» // Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2009. № 42. С. 24.
  6. Chaw L. The modern aspects of antiviral treatment the patients with chronic viral hepatitis B. Hepatology 2008;34:1234-39.
  7. Cooksley W.G. Pegylated interferon - alfa2a ("Pegasys") in patients with chronic viral hepatitis B. Hepatology 2002;36:A374.
  8. Hadziyannis S, Lau GKK, Marcellin P, et al. Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®). J Hepatol 2005;42(2):178 (Abstract).
  9. Moucari R. et al. Hepatitis B virus surface antigen levels during and after pegylated interferon - alfa 2a treatment might be predictors of sustained viral response. Hepatology 2009;49:1151.
  10. Brunetto M.R. et al. Predicting Responce to hepatitis B virus therapy. Hepatology 2009;49:1141.
  11. Marcellin P. Early HBsAg Decline Predicts Sustained Response to Pegylated Interferon. Hepatology 2009;49:1162.
  12. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2500&mid=1085056570&magid=186

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies